Login to Your Account

MacroGenics 'Serves' DART Deal Worth Potential $1B

By Peter Winter
BioWorld Insight Editor

Thursday, September 20, 2012

MacroGenics' DART technology for generating bi‐specific antibodies has attracted a great deal of interest from pharmaceutical and biotechnology companies. In the past couple of years the company has forged alliances with Boehringer Ingelheim, Green Cross (Korea), Pfizer Inc. and Servier. The latest deal brings Servier back to the table.

The French company has just entered an option agreement with MacroGenics for the development and commercialization of Dual‐Affinity Re‐Targeting (DART) products directed at three undisclosed tumor targets.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription